Abstract:Introduction Pre-transplant leukemic load significantly impacts relapse and long-term survival in patients with acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS). A prolonged duration of busulfan administration was reported as a safe myeloablative option with less toxicity and allows the addition of epigenetic agents, like chidamide, which may be synergistic with conditioning chemotherapy and may further improve disease control. Meanwhile, Pre-conditioning busulfan may play a priming role in enhancing the sensitivity of tumor cells to the following conditioning therapy. Here we report the safety and preliminary efficacy of chidamide and fractionated busulfan regimen in patients with AML or MDS who could not clear leukemia cells before transplantation. Methods We enrolled AML or MDS patients with residual or active disease after at least one line of standard therapy. Eligible patients received fractionated busulfan at a total dose of 12.8 mg/kg within 2 weeks. The first two doses of busulfan (1.4 mg/kg IV each) were administered on days -14 and -13. The rest of the busulfan was given on days -7 to -4. Fludarabine and cytarabine were given on days -7 to -3. Chidamide 30 mg twice weekly was given from day -14 to + 3. Peripheral stem-cell were used as grafts harvested from HLA-matched sibling donors (MSD), matched unrelated donors (MUD), or haploidentical donors (HID). Post-transplantation acute graft versus host disease (GVHD) prophylaxis consisted of cyclophosphamide on day +3 to +4, and cyclosporine started on day +5. For HID transplant recipients, mycophenolate mofetil was added from day +5 to day +35. Follow-up examinations were scheduled at +1, +2, +3, +4, +6, +9, +12, +18, and +24 months post-transplant. Donor lymphocyte infusion was not administered prophylactically in this trial. Results Twenty-six patients with de novo AML (n=19), secondary AML transformed from MDS (n=4), or MDS-EB2 (n=3) were enrolled with a median age of 48 years (range, 23~65 years). Patient and disease characteristics are summarized in Table 1. Nineteen patients had adverse risk karyotype according to European LeukemiaNet risk stratification. They received MSD (n=7), MUD (n=2), or HID (n=17) HSCT. Pre-transplant tests revealed that 14 of the patients had MRD (n=14, blast cells＜5% in the bone marrow), and 12 had active disease (blast cells ≥5%, including 4 who had blast cells ≥20%). The median pre-transplant blast cells were 7.5%. All patients successfully finished scheduled conditioning. Neutrophils and platelets engrafted at a median of 13 days (range,11-18 days) and 16 days (range, 11-53 days) post-transplant, respectively. All patients reached MRD negative with full donor chimerism at day +30. Cumulated incidence of grade II to IV and grade III to IV acute GvHD were 12.5% and 5.3% respectively. The median follow-up time was 13 months (2-45.5 months). For the whole cohort, the estimated 1-year progression free survival (PFS) and overall survival (OS) were 59.1% and 69.0% (Figure-1A). For patients with MRD+ or active disease, estimated 1-year PFS are 77.1% and 45.5%, respectively (Figure-1B), and estimated 1year OS of these two groups of patients are 87.5% and 63.6%, respectively (Figure-1C). Three patients died from pulmonary infections (2 with COVID-19 and 1 with cytomegalovirus) in CR at 5.8, 6.9, and 11.5 months post-transplant. The incidence of non-relapse mortality at 6 months and 1 year post-transplant was 4.8% and 16.3% respectively (Figure-1D). Conclusion Fractionated-busulfan based myeloablative conditioning regimen with chidamide confers survival advantage and good tolerance in acute leukemia and MDS patients with residual or active disease.

[The Efficacy and Safety of Modified Busulfan/fludarabine Conditioning Regimen in Elderly or Drug-Intolerable Patients with Hematologic Malignancies].

Combination of Busulfan with Increased-Dose of Fludarabine As Conditioning Regimen for MDS and MDS-AML Patients with Allo-Hsct

Busulfan and Cyclophosphamide for Hemopoietic Stem Cell Transplantation from Related and Unrelated Donors in Patients with Myelodysplastic Syndrome

[Study on Unrelated Donor Allogeneic Bone Marrow Transplantation with Bu-CY2 Conditioning Regimen for Myelodysplastic Syndrome].

Control Study of Fludarabine Instead of Cyclophosphamide in Modified Busulfan-Cyclophosphamide As a Myeloablative Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation for Treatment of Acute Leukemia

[Reduced Intensity of BuCy Conditioning Regimen for Transplantation in the Treatment of Malignant Hematologic Diseases].

Fludarabine- and Low-Dose Cyclophosphamide-Based Conditioning Regimens for Unmanipulated Hematopoietic Cell Transplantation from Unrelated Donors and Matched Siblings in Patients with Fanconi Anemia: Results from the Cbmtr

Fludarabine and busulfan as a myeloablative conditioning regimen for allogeneic stem cell transplantation in high- and standard-risk leukemic patients

Busulfan Combined with Increased-Dose of Fludarabine As Conditioning Regimen for Allogeneic Stem Cell Transplantation in Intermediate and High-Risk Acute Myeloid Leukemia

Outcomes following HSCT using fludarabine replacing cyclophosphamide as a new preconditioning regimen for treatment of hematologic malignancies

Evaluate the Efficacy of Myeloablative Conditioning Regimens for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myelogenous Leukemia at BTH, Vietnam

Long-Term Efficacy Analysis of Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of Acute Myeloid Leukemia Using Melphalan Instead of Cyclophosphamide As a Myeloablative Conditioning Regimen

Graft-Versus-Host Disease Following Myeloablative Busulfan Plus Fludarabine And Busulfan Plus Cyclophosphamide For Allogeneic Hematopoietic Stem Cell Transplantation In Acute Myeloid Leukemia In First Complete Remission

Haploidentical Stem Cell Transplantation With a Novel Conditioning Regimen in Older Patients: A Prospective Single-Arm Phase 2 Study

Reduced-Toxicity Myeloablative Conditioning Consisting of Fludarabine/Busulfan/Low-Dose Total Body Irradiation/Granulocyte Colony-Stimulating Factor-Combined Cytarabine in Single Cord Blood Transplantation for Elderly Patients with Nonremission Myeloid Malignancies

Fludarabine, busulfan, and melphalan conditioning regimen in allogeneic hematopoietic stem cell transplantation for adult patients with myeloid malignancies: A multicenter retrospective study

Busulfan Plus Fludarabine Compared With Busulfan Plus Cyclophosphamide for AML Undergoing HLA-Haploidentical Hematopoietic Cell Transplantation: A Multicenter Randomized Phase III Trial

A Modified Conditioning Regimen Based on Low‐dose Cyclophosphamide and Fludarabine for Haploidentical Hematopoietic Stem Cell Transplant in Severe Aplastic Anemia Patients at Risk of Severe Cardiotoxicity

Reduced intensity conditioning regimen of fludarabine, busulfan, ATG based haploidentical stem cell transplantation for older or unfit patients

Reduced‐intensity conditioning with fludarabine/busulfan versus fludarabine/low‐dose melphalan in patients with non‐Hodgkin lymphoma undergoing allogeneic haematopoietic stem cell transplantation

Myeloablative Fractionated Busulfan Conditioning Regimen with Chidamide in Patients with AML/MDS Less Than Complete Remission